Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Lilly Japan Adds Tablet Formulation for Retevmo
September 19, 2025
- Nihon Chouzai Tender Offer Completed, Set to Delist under Advantage Partners
September 18, 2025
- RaQualia’s Reflux Therapy Tegoprazan Debuts in India
September 18, 2025
- Eisai’s Etalanetug Snags FDA Fast Track Designation
September 18, 2025
- Daito Wins China Approval for Celecoxib, 2nd Generic in Market
September 18, 2025
- Alnylam Sees Japan Business Doubling as Amvuttra Expands into ATTR-CM
September 17, 2025
- Kyorin/aTyr’s Efzofitimod Misses Primary Goal in Global PIII Trial
September 17, 2025
- Mitsubishi, J&J to End Stelara Co-Promotion in Japan at Year-End
September 17, 2025
- ASKA Presses Dalton Again for Stake Plan Details after Public Statement
September 17, 2025
- Daiichi Bags FDA Breakthrough Therapy Status for Anti-CDH6 ADC
September 17, 2025
- AbbVie Japan Seeks Rinvoq Label Expansion for Polyarticular JIA
September 16, 2025
- Clenafin Authorized Generic Hits Japan Market: Kaken
September 16, 2025
- Lilly Confirms Safety of Oral GLP-1 Orforglipron in Japan PIII
September 16, 2025
- Pfizer’s Ulcerative Colitis Drug Velsipity Now Available in Japan
September 16, 2025
- Predictability Key to Novartis’ Japan Investment, Says International Chief
September 16, 2025
- Eisai Sees “Best-in-Class” Promise for E2086 as Once-Daily Narcolepsy Drug
September 12, 2025
- LEO Pharma Reinforces Japan Push toward Dermatology Leadership
September 12, 2025
- Enhertu’s Tumor-Agnostic Use Now under EU Review: Daiichi Sankyo
September 12, 2025
- Sawai, Nichi-Iko to Consolidate 15 APIs as Sector Tackles Small-Lot Production
September 11, 2025
- Sawai and T’s Pharma Won Forxiga Generics by Skirting Patent, Will the Strategy Hold?
September 11, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…